MXCT
VERY BADMaxCyte to Delist from AIM, Retain Nasdaq Listing
The medical device company is cancelling the admission of its shares to trading on the AIM market, with the last day of dealings on June 25, 2025.
MXCT
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
Upcoming Events
December 31, 2025
Projected cash and investments balance of $160M
High Impact Event
No data available for this timeframe
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The healthcare company reports a change in substantial shareholding by BlackRock, Inc.
MXCT
NEUTRALMaxCyte and Ori Biotech Collaborate to Improve Cell Therapy Manufacturing
The healthcare technology companies are collaborating to improve the efficiency and scalability of cell therapy manufacturing.
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The healthcare company reports a change in substantial shareholding by BlackRock, Inc.
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The healthcare company reports a change in substantial shareholding by BlackRock, Inc.
MXCT
NEUTRALMaxCyte Announces Change in Shareholding
The healthcare company has announced a change in shareholding, with BlackRock, Inc. increasing its stake in the business.
MXCT
NEUTRALMaxCyte Announces Director Shareholding Change
The medical device company has announced a change in director shareholding.
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The medical device company reports a change in substantial shareholding by BlackRock, Inc.
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The healthcare company reports a change in substantial shareholding by BlackRock, Inc.
MXCT
NEUTRALMaxCyte Announces Director Dealings
The healthcare company has announced changes to its major shareholders.